Related Experiment Video
Updated: May 5, 2026

Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts
Published on: March 22, 2017
Advances in fibroblast-based cardiac reprogramming in the treatment of heart disease
Yuanyuan Jin1,2, Yuchang Liu1,3, Ao Ge1,3
1Southwest Medical University, Luzhou, China.
Background:
Due to population aging and a wide range of risk factors, coupled with the limited regenerative capacity of the myocardium, the prevention and treatment of cardiovascular diseases remain challenging.
Methods:
This review evaluates cardiac reprogramming as an innovative approach to directly convert fibroblasts into functional cardiomyocytes through genetic or pharmacological means. We focus on its application in myocardial infarction, ischemia-reperfusion injury, and heart failure, and discuss strategies for improving reprogramming efficiency and recent advances in nanomaterial-assisted delivery.
Results:
Cardiac reprogramming shows potential in reducing fibrosis and restoring function, with efficiency improved through novel delivery systems and optimized protocols.
Conclusion:
This technology represents a promising strategy for cardiac regeneration, future work should focus on optimizing reprogramming protocols and developing clinically viable delivery systems to accelerate therapeutic translation.
Related Concept Videos
Development of the Heart
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart...
Heart Failure II: Pathophysiology
Cardiomyopathy V: Interprofessional Care

